Biotech 4DMT heads to three March healthcare investor conferences
4D Molecular Therapeutics (FDMT) announced that its management will participate in three healthcare investor conferences in March 2026. The company will present and hold one-on-one meetings at events hosted by TD Cowen, Leerink, and Barclays, with webcasts of the presentations available for up to one year on its investor relations site. This news comes as the company continues to advance its late-stage biotechnology therapeutics, including 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis.
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) announced that its management will present and hold one-on-one meetings at several upcoming investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and Barclays 28th Annual Global Healthcare Conference. The company is a late-stage biotechnology firm focused on developing durable, disease-targeted therapeutics, with lead product candidates 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that on February 10, 2026, its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees. These grants were made under the company’s 2025 Employment Inducement Award Plan, in accordance with Nasdaq rules, to incentivize new hires. 4DMT is a late-stage biotechnology company focused on developing gene therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) announced that on February 10, 2026, its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees. These grants were made under the Company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
Biotech 4DMT hands 124,200 stock units to just nine recruits
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees on February 10, 2026. These awards were made under the company's 2025 Employment Inducement Award Plan, following Nasdaq Global Market Rule 5635(c)(4), to attract new talent. This move is consistent with the company's routine corporate equity awards, alongside its ongoing clinical milestones and corporate updates.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees on February 10, 2026. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company developing therapeutics for retinal diseases and cystic fibrosis, with lead candidates 4D-150 and 4D-710 respectively.
4D Molecular Therapeutics Advances Toward Phase 3 Milestones in Retina Gene Therapy
4D Molecular Therapeutics is progressing its gene therapy programs, particularly focusing on ocular vascular diseases like wet age-related macular degeneration (AMD). The company is accelerating towards key clinical benchmarks, including broader global expansion of trials and evaluation of long-term data from existing Phase 2 programs. In 2026, 4D Molecular Therapeutics plans to expand into diabetic macular edema and has various clinical and financial milestones scheduled.
Barclays flags M&A tailwinds and pricing relief as upside catalysts for 4D Molecular Therapeutics, Inc. (FDMT)
Barclays has identified potential catalysts for 4D Molecular Therapeutics, Inc. (FDMT), including tailwinds from mergers and acquisitions (M&A) and relief in drug pricing. These factors are seen as potential drivers for the company's stock performance.
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-1 Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), ahead of initial projections. The trial overenrolled with more than 500 patients, reflecting strong interest in 4D-150 as a potential backbone therapy to reduce treatment burden. Topline data from 4FRONT-1 is expected in the first half of 2027, and enrollment for the second Phase 3 study, 4FRONT-2, is on track for completion in the latter half of 2026.
4D Molecular (FDMT) Completes Enrollment for Key Phase 3 Wet AMD Trial
4D Molecular Therapeutics (FDMT) has completed enrollment for its pivotal Phase 3 clinical trial, 4FRONT-1, which investigates the efficacy of 4D-150 for wet age-related macular degeneration (AMD). The trial's primary goal is to demonstrate the non-inferiority of 4D-150 compared to aflibercept, with results expected in the first half of 2027. Despite strong liquidity, the company faces significant profitability challenges, as indicated by negative margins and declining revenue growth.
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics (Nasdaq: FDMT) announced the completion of enrollment for its 4FRONT-1 Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), achieving target enrollment in approximately 11 months with over 500 randomized patients. Topline data for 4FRONT-1 is anticipated in the first half of 2027, while enrollment for the second Phase 3 trial, 4FRONT-2, is expected to conclude in the second half of 2026, with topline results projected for the second half of 2027. This milestone underscores continued progress in 4DMT's late-stage wet AMD program and reflects strong interest from investigators and patients for a potential new treatment paradigm.
4Dmt completes enrollment for 4Front-1 phase 3 Clinical Trial of 4D-150 in wet AMD
4D Molecular Therapeutics (4Dmt) has successfully completed enrollment for its 4Front-1 Phase 3 Clinical Trial of 4D-150, a genetic medicine product candidate, targeting wet age-related macular degeneration (wet AMD). This milestone was announced on February 9, 2026. 4Dmt is a clinical-stage genetic medicines company with a focus on ophthalmology and pulmonology, and 4D-150 is one of several product candidates in clinical trials.
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-1 Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), ahead of initial projections. The trial overenrolled with over 500 patients, reflecting strong interest, and topline data is expected in the first half of 2027. This milestone highlights the potential of 4D-150 as a backbone therapy to reduce treatment burden for wet AMD patients.
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-1 Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), ahead of schedule. The trial overenrolled with over 500 patients, reflecting strong interest in 4D-150 as a potential long-term treatment to reduce injection burden. Topline data from 4FRONT-1 is expected in the first half of 2027, and enrollment for the second Phase 3 study, 4FRONT-2, is also on track.
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-1 Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), ahead of schedule. The trial overenrolled with over 500 patients, demonstrating strong interest in 4D-150 as a potential backbone therapy to reduce the treatment burden for wet AMD patients. Topline data for 4FRONT-1 is expected in the first half of 2027, while the second Phase 3 study, 4FRONT-2, is on track for enrollment completion in late 2026.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
4D Molecular Therapeutics (NASDAQ:FDMT) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 12-month price target of $33.25. The clinical-stage biotech company, which focuses on targeted gene therapies for rare diseases, is currently unprofitable with minimal revenue. Shares recently traded at $9.29, giving the company a market capitalization of approximately $530.7 million.
Barclays flags M&A tailwinds and pricing relief as upside catalysts for 4D Molecular Therapeutics, Inc. (FDMT)
This article identifies potential upside catalysts for 4D Molecular Therapeutics, Inc. (FDMT) according to Barclays. The key drivers highlighted are M&A tailwinds and pricing relief, suggesting improved market conditions or strategic moves could significantly benefit the company.
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)
Barclays has initiated coverage on 4D Molecular Therapeutics, Inc. (FDMT) with an Overweight rating and a $33 price target, citing strong biotech fundamentals, undervaluation, anticipated M&A tailwinds, and pricing relief as key upside catalysts. The company also provided a 2026 corporate update, detailing advancements in its Phase 3 trials for 4D-150 in Wet AMD and Diabetic Macular Edema, as well as updates expected for its Phase 2 cystic fibrosis program. FDMT is a clinical-stage biotechnology company developing targeted gene therapies for serious diseases.
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)
Barclays initiated coverage of 4D Molecular Therapeutics, Inc. (FDMT) with an Overweight rating and a $33 price target, citing M&A tailwinds, solid biotech fundamentals, and anticipated pricing relief as positive catalysts. The company also provided a corporate update, detailing advancements in its 4FRONT Phase 3 trials for Wet AMD and plans for other clinical programs in 2026. FDMT is a clinical-stage biotechnology company focused on developing targeted gene therapies.
Barclays Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Overweight Recommendation
Barclays has initiated coverage of 4D Molecular Therapeutics (FDMT) with an "Overweight" recommendation. Analysts project a significant upside of 292.71% for the stock, with an average one-year price target of $33.77 per share. Fund sentiment for FDMT is largely bullish, with major institutional investors like Bvf, Ra Capital Management, and Goldman Sachs Group holding substantial positions.
FDMT: Barclays Initiates Coverage with Overweight Rating and $33 Price Target | FDMT Stock News
Barclays has initiated coverage on 4D Molecular Therapeutics (FDMT) with an "Overweight" rating and a price target of $33 USD. This new rating comes as analysts continue to evaluate the company, with an average target price of $33.11 from 9 analysts, implying a significant upside from its current price. 4D Molecular Therapeutics is a clinical-stage gene therapy company developing product candidates across ophthalmology, cardiology, and pulmonology.
4D Molecular Therapeutics Restructures Equity via Warrant Exchange
4D Molecular Therapeutics restructured its equity by exchanging 6.6 million common shares for an equal number of pre-funded warrants with RA Capital Healthcare Fund and Biotechnology Value Fund on January 22, 2026. This move shifts institutional holdings from common stock to warrants, potentially offering flexibility with ownership limits and future dilution. The company now has 51,007,874 shares outstanding, excluding 16,935,665 additional shares from existing pre-funded warrants.
4D Molecular Therapeutics: A Valuation Disconnect Amidst Clinical Progress
Shares of 4D Molecular Therapeutics (US35104E1001) closed at $7.96, despite analysts setting a median price target of $33.00, indicating a potential upside exceeding 300%. The company has a strong cash position of $514 million, which is more than its market capitalization, and is funding operations through 2028. The market's focus is on the Phase 3 trial for 4D-150, with topline results expected in the first half of 2027.
4D Molecular (FDMT) Grants RSUs to New Employees
4D Molecular Therapeutics (FDMT) has granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees to attract talent, utilizing its 2025 Employment Inducement Award Plan. Despite its innovative gene therapy pipeline, the company faces significant financial challenges, including negative revenue growth and substantial losses. The article highlights the company's strong liquidity but also flags warning signs in its Altman Z-Score and Beneish M-Score, suggesting financial distress and potential manipulation.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees on January 13, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapeutics for diseases like wet age-related macular degeneration and cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees on January 13, 2026. These RSUs were issued under the Company’s 2025 Employment Inducement Award Plan, approved by the board to attract new talent. 4DMT is a late-stage biotechnology company developing therapeutics for diseases like wet age-related macular degeneration and cystic fibrosis.
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees
4D Molecular Therapeutics recently issued 23,600 Restricted Stock Units (RSUs) to four new non-executive employees on January 13, 2026, as part of an incentive program to attract and retain talent. The company is advancing with its lead product, 4D-150, in Phase 3 trials for retinal vascular diseases, and 4D-710, a gene therapy for cystic fibrosis, showing significant potential in the therapeutic landscape. Analysts have varying price targets for FDMT, with an average 1-year target of $29.40, reflecting the company's strong product pipeline and financial position.
Biotech 4DMT hands 23,600 stock units to four new hires under award plan
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees on January 13, 2026. These RSUs were issued under the company’s 2025 Employment Inducement Award Plan, approved by the board in February 2025 under Nasdaq Rule 5635(c)(4). This action reflects an ongoing trend of equity-based hiring incentives, following similar grants in December 2025.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees on January 13, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan, approved in February 2025, to attract new talent. 4DMT is a late-stage biotechnology company focused on advancing durable and disease-targeted therapeutics, with lead product candidates 4D-150 and 4D-710 in clinical development.
Fabry Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics
The global Fabry Disease market is projected for significant growth, reaching approximately USD 1,700 million in 2024 and expanding through 2034, driven by increasing prevalence and the introduction of new therapies. Key players like Sangamo Therapeutics, Sanofi Genzyme, and Amicus Therapeutics are advancing pipeline products, including gene therapies like ST-920, which is pursuing accelerated FDA approval. The United States currently holds the largest market share, with Germany leading in Europe, and the market is expected to be reshaped by emerging treatments addressing the unmet needs of this rare genetic disorder.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages
4D Molecular Therapeutics (NASDAQ:FDMT) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month target price of $28.70. Despite this, the company reported a quarterly EPS beat but missed revenue estimates and remains unprofitable. Insider selling activity has also been noted, while institutional investors hold a significant portion of the stock.
4DMT Provides Company Update and Anticipated Development Milestones for 2026
4D Molecular Therapeutics (4DMT) provided a corporate update and outlook for 2026, highlighting significant progress in its 4D-150 program for retinal vascular diseases, including exceeding enrollment expectations for wet AMD trials and anticipated Phase 3 initiation for DME. The company also announced leadership team evolution, new board appointments, and updated milestones for other pipeline programs. 4DMT expects its $514 million cash reserves to fund operations into the second half of 2028.
Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026.
Certain warrants of 4D Molecular Therapeutics, Inc. (FDMT) are under a lock-up agreement that began on November 6, 2025, and ends on January 6, 2026. This 61-day lock-up prevents executive officers and directors from selling or transferring common stock or convertible securities without the consent of Leerink Partners LLC and Evercore Group L.L.C. The article also provides real-time stock data and recent company news.
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely
4D Molecular Therapeutics, Inc. (FDMT) is receiving significant attention due to its strong analyst ratings, with an 82% 'Buy' or equivalent rating and a median price target indicating over 300% upside potential. The company recently reported positive interim clinical data from its 4D-710 Phase 1 AEROW trial for cystic fibrosis lung disease, showing favorable safety profiles and promising therapeutic activity. Additionally, the article notes an insider transaction where the CLO offloaded shares, and positions FDMT as a potential "Get Rich Fast Stock" while suggesting other AI stocks might offer greater upside.
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is gaining attention as a "Get Rich Fast Stock," with analysts giving it a "Buy" rating and a median price target suggesting over 300% upside potential. The company recently reported positive interim clinical data from its 4D-710 Phase 1 AEROW clinical trial for cystic fibrosis lung disease, showcasing favorable safety profiles and promising therapeutic activity. Despite this, the article suggests some AI stocks may offer even greater promise for returns.
Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock
Ashoo Gupta, VP, Finance and Controller at 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), sold 389 shares of common stock for $3,376 and exercised 1,086 Restricted Stock Units. This insider transaction comes amidst positive developments for the company, including a new CFO appointment, increased price targets from RBC Capital and Leerink Partners, and a significant license agreement with Otsuka Pharmaceuticals. Morgan Stanley also upgraded the stock following positive clinical trial results for its 4D-150 therapy.
Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock
Ashoo Gupta, VP, Finance and Controller at 4D Molecular Therapeutics (NASDAQ:FDMT), sold 389 shares of common stock for $3,376 and exercised 1,086 Restricted Stock Units. This news comes amid positive developments for the company, including a new CFO appointment, increased price targets from RBC Capital and Leerink Partners, and a significant licensing deal with Otsuka Pharmaceuticals for its 4D-150 therapy.
4D Molecular falls after early-stage trial data for cystic fibrosis therapy
4D Molecular Therapeutics (NASDAQ:FDMT) shares dropped following the release of interim data from the Phase 1/2 AEROW clinical trial of 4D-710 for cystic fibrosis (CF) lung disease. While low doses showed minimal adverse events and some participants saw improved lung function, higher doses led to more grade 1 and 2 adverse events, and a majority of participants experienced grade 3 or 4 events, mainly transaminitis. The trial's primary goals are safety and tolerability, with additional readouts on lung function and gene expression expected in 2025.
4D Molecular Therapeutics Gains Momentum from Clinical Data and Index Inclusion
4D Molecular Therapeutics Inc. is experiencing significant momentum due to positive clinical trial data, a secure financial outlook, and increased market visibility through its inclusion in the S&P Biotechnology Select Industry Index. The company's 4D-710 candidate showed promising early results in a Phase 1 study, and its financial runway is extended into late 2028, bolstered by a partnership with Otsuka Pharmaceuticals. These factors collectively provide a strong foundation for the company's upcoming clinical milestones, including Phase 3 trials for 4D-150 and Phase 2 development for 4D-710.
4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains
Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) recently experienced a 20% loss over the past week, though they have seen longer-term gains. Institutions collectively hold a substantial 50% ownership, indicating significant influence over the company's share price. Insiders have also been selling shares, and the top 10 shareholders account for more than half of the share register, suggesting concentrated ownership.
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to S&P Biotechnology Select Industry Index
4D Molecular Therapeutics, Inc. (NasdaqGS:FDMT) has been included in the S&P Biotechnology Select Industry Index. This news follows a series of recent announcements from the company, including positive interim clinical data for its 4D-710 Aerow Phase 1 trial in Cystic Fibrosis lung disease and a strategic partnership with Otsuka Pharmaceutical Co. Ltd.
4D Molecular Therapeutics Executive Sells Shares
Bizily Scott, Chief Legal Officer and 10% Owner of 4D Molecular Therapeutics (FDMT), sold 1,635 shares of common stock for $17,821 on December 16, 2025. This transaction was part of a 10b5-1 trading plan adopted in June 2025, leaving Scott with 3,594 directly owned shares. The sale details are publicly available via an SEC Form 4 filing.
Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT)
Analysts have shown bullish sentiments on several healthcare stocks, specifically Novan (NOVN), 4D Molecular Therapeutics (FDMT), and Insmed (INSM). Bank of America Securities maintained a Buy rating on 4D Molecular Therapeutics with a $31.00 price target, while RBC Capital maintained a Buy rating on Insmed with a target of $195.00. The article highlights strong buy consensus ratings and significant upside potential for both FDMT and INSM based on analyst targets.
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)
4D Molecular Therapeutics (FDMT) is largely focused on 4D-150 for wet AMD, with a pivotal Phase 3 readout expected in 2027, and its financial runway has been extended into 2028 thanks to an $85M upfront payment from a recent Otsuka partnership. While early data for 4D-710 in cystic fibrosis shows some promise, it lacks clear efficacy on key endpoints, leaving its future and market reaction uncertain. Despite significant market opportunities, the current data does not yet support a bullish investment stance, and material financial risk remains if pivotal results disappoint.
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation
Chardan Capital has reiterated its Buy recommendation for 4D Molecular Therapeutics (FDMT), with an analyst price forecast suggesting a 288.87% upside to $33.77/share. The company's projected annual revenue is 2MM, an increase of 1,280.00%, while the projected annual non-GAAP EPS is -3.72. Fund sentiment is bullish, with institutional ownership reflecting 43,016K shares despite a slight decrease in the number of reporting funds.
Early test of new cystic fibrosis lung treatment shows promising results
4D Molecular Therapeutics announced positive interim Phase 1 AEROW data for its investigational cystic fibrosis lung disease treatment, 4D-710, demonstrating durable CFTR transgene expression and clinically meaningful improvements in lung function. Despite the positive clinical data, the market reacted negatively, with FDMT stock declining by 20.05% on the news day, suggesting that investors may have focused on prior valuation gains or event-driven positioning. The company plans to complete Phase 2 dose-expansion enrollment in the first half of 2026.
4D Molecular Therapeutics (FDMT) director reports 9,333-share option exercise
4D Molecular Therapeutics director Charles Theuer reported exercising a stock option for 9,333 shares of common stock at $1.14 per share on December 12, 2025. This transaction involved a fully vested stock option, and post-transaction, Theuer directly beneficially owned 41,684 shares of FDMT common stock with no remaining derivative securities from this specific grant. The SEC Form 4 filing details the acquisition, price, and the resulting beneficial ownership.
Key facts: 4D Molecular Therapeutics reports positive trial results; Scott Bizily files Form 144
4D Molecular Therapeutics (FDMT) announced positive interim Phase 1 trial results for 4D-710, showing lasting lung function improvements and a good safety profile in cystic fibrosis patients. Additionally, Scott Bizily, associated with 4D Molecular Therapeutics, filed a Form 144 to sell 1,635 restricted shares.
4D Molecular posts Phase 1 trial data for cystic fibrosis drug
4D Molecular Therapeutics (FDMT) saw a ~15% drop after releasing updated data from an early-stage trial for 4D-710, its experimental therapy for cystic fibrosis lung disease. The data cut as of December 1, 2025, from the Emeryville, California-headquartered company, did not appear to satisfy investors.
4D Molecular Therapeutics Announces Positive Interim Clinical Data from 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
4D Molecular Therapeutics reported positive interim clinical data from its 4D-710 Phase 1 AEROW trial for cystic fibrosis lung disease. The 2.5E14 vg dose cohort showed clinically meaningful activity in multiple endpoints, including ppFEV1, LCI2.5, and quality of life, confirming 2.5E14 vg as the Phase 2 dose. The company aims to complete enrollment for the Phase 2 Dose-Expansion cohort in the first half of 2026, with an update expected in the second half of 2026.
